Royalty Pharma (RPRX) risk factors

Royalty Pharma completed its internal management transition, taking on direct overhead, employee liabilities, and subsidiary dependence risks. Litigation risks emerged regarding Vertex underpaying Alyftrek royalties. Top five product franchises generated 61% of royalty receipts.

Royalty Pharma faces high dependence on its external manager for sourcing biopharmaceutical royalties and key executives like Mr. Legorreta. High leverage and concentrated product revenue of 64% from top five franchises drive business risk. Financial results are exposed to volatile amortized cost accounting for royalty assets and intense market competition.